Adagene and Merck Showcase ADG126+Keytruda Safety and Activity in MSS-CRC
Adagene presented Phase I data of its ADG126 combined with Merck’s KEYTRUDA in late-line microsatellite stable colorectal cancer at the Oppenheimer conference. The update emphasized preliminary safety profile and early clinical activity signals across evaluated patients.
1. Oppenheimer Conference Presentation
Adagene delivered a presentation at the Oppenheimer Healthcare conference showcasing data from its ongoing Phase I study of ADG126 in combination with KEYTRUDA for late-line microsatellite stable colorectal cancer. The talk underscored the collaboration with Merck and highlighted the strategic focus on challenging MSS-CRC populations.
2. Preliminary Clinical Data
The update detailed preliminary safety findings, reporting no new adverse signals and manageable tolerability. Early clinical activity signals were observed, suggesting potential synergistic anti-tumor effects warranting further investigation in expanded cohorts.